扩大标准供体肝移植终末缺血期低温氧合灌注:多中心随机对照试验HOPExt
HOPExt试验是一项开放标签、多中心、前瞻性随机对照研究,比较扩大标准供体(ECD)肝移植中终末缺血期低温氧合灌注(HOPE)与静态冷保存的效果。主要目的是评估HOPE在术后7天内减少早期移植物功能障碍的疗效。试验于2019年9月10日开始入组,正在 ongoing。
要点
- HOPExt试验比较HOPE与静态冷保存用于ECD肝移植。
- 主要终点为术后7天内早期移植物功能障碍。
- 试验为开放标签、多中心、前瞻性随机对照设计。
核心结论
- HOPE可能通过减少再灌注损伤改善ECD肝移植结局,但本方案未报告疗效结果。
研究设计与样本
- HOPExt试验为开放标签、多中心、全国性、前瞻性、随机对照研究,采用两组平行设计,以静态冷保存为对照。
- 纳入等待肝移植的成人肝衰竭或肝硬化患者和/或需肝移植的肝脏恶性肿瘤患者,接受脑死亡供者ECD肝移植。
- 实验组ECD肝移植物先经经典静态冷保存(4°C),随后接受1至4小时低温氧合灌注(HOPE)。
- 对照组接受经典静态冷保存,即肝移植金标准操作。
- 主要目的为比较HOPE与简单静态冷保存相比,在减少脑死亡供者ECD肝移植术后7天内早期移植物功能障碍方面的疗效。
主要发现
- 本方案未报告试验结果。
- 试验入组于2019年9月10日开始,正在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given the scarce donor supply, an increasing number of so-called marginal or extended criteria donor (ECD) organs are used for liver transplantation. These ECD liver grafts are however known to be associated with a higher rate of early allograft dysfunction and primary non-function because of a greater vulnerability to ischemia-reperfusion injury. The end-ischemic hypothermic oxygenated machine perfusion (HOPE) technique may improve outcomes of liver transplantation with ECD grafts by decreasing reperfusion injury. METHODS: HOPExt trial is a comparative open-label, multicenter, national, prospective, randomized, controlled study, in two parallel groups, using static cold storage, the gold standard procedure, as control. The trial will enroll adult patients on the transplant waiting list for liver failure or liver cirrhosis and/or liver malignancy requiring liver transplantation and receiving an ECD liver graft from a brain-dead donor. In the experimental group, ECD liver grafts will first undergo a classical static cold (4 °C) storage followed by a hypothermic oxygenated perfusion (HOPE) for a period of 1 to 4 h. The control group will consist of the classic static cold storage which is the gold standard procedure in liver transplantation. The primary objective of this trial is to study the efficacy of HOPE used before transplantation of ECD liver grafts from brain-dead donors in reducing postoperative early allograft dysfunction within the first 7 postoperative days compared to simple cold static storage. DISCUSSION: We present in this protocol all study procedures in regard to the achievement of the HOPExt trial, to prevent biased analysis of trial outcomes and improve the transparency of the trial results. Enrollment of patients in the HOPExt trial has started on September 10, 2019, and is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov NCT03929523. Registered on April 29, 2019, before the start of inclusion.
引用
- Pradat P, Pantel S, Maynard M, et al. End-ischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial-HOPExt. Trials. 2023. PMID: 37280696. doi:10.1186/s13063-023-07402-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。